Kristian Thon

  • Consultant; MD

Publications 2024

Löffeler S, Bertilsson H, Müller C, Aas K, Haugnes HS, Aksnessæther B, Pesonen M, Thon K, Tandstad T, Murtola T, Poulsen MH, Nordstrøm T, Vigmostad MN, Ottosson F, Holmsten K, Christiansen O, Slaaen M, Haug ES, Storås AH, Asphaug L, Rannikko A, Brasso K, Scandinavian Prostate Cancer Group (SPCG) and the Norwegian Get‐Randomized (GRand) Initiative (2024)
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
BJU Int, 133 (6), 680-689
DOI 10.1111/bju.16314, PubMed 38469686

Publications 2023

Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K et al. (2023)
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial
Eur Urol Oncol, 7 (3), 462-468
DOI 10.1016/j.euo.2023.09.007, PubMed 37821242

Publications 2020

Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A et al. (2020)
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases
Eur Urol Focus, 7 (2), 241-244
DOI 10.1016/j.euf.2020.12.010, PubMed 33386290

Publications 2018

Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A (2018)
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Eur J Cancer, 97, 33-40
DOI 10.1016/j.ejca.2018.03.007, PubMed 29685343

Page visits: 826